Abstract: Objective To investigate whether clinical and pathological factors and molecularsubtypes of breast cancer was able to predict pathological complete response (pCR) after neoadjuvant chemotherapy using docetaxel plus epirubicin, cytoxan (TEC-NAC). Methods Two hundred and fourteen patients who underwent 4 cycles of TEC-NAC were retrospectively studied. In Core-needle biopsy specimens, estrogen receptor(ER), progesterone receptor(PR), human epidermal growth factor receptor-2(HER2), Ki67 and p53 were detected by immunohistochemical assay, and HER2 was also detected by Fluorescence In Situ Hybridization(FISH). Breast cancer was divided into 4 molecular subtypes of LuminalA, LuminalB, HER2 overexpression and triple negative breast cancer based on the expression levels of ER, PR, HER2 and Ki67.The correlation between these Factors and pCR was analyzed. Results Among all 214 cases, pCR was 14.0% (30/214) after 4 cycles of TEC-NAC. In the univariate analysis, the correlation between expressions of ER, PR, Ki67 and molecular subtypes of breast cancer and pCR were significant (P<0.05 all). pCR rates were LuminalA CI: 0.136 to 0.712; P=0.006) and Ki67 (OR=2.788，95% CI：1.061 to 7.327；P=0.038). Conclusion ER, PR negative expression, Ki67-positive and molecular subtypes of breast cancer might be the predictors of pCR.